Soteria is developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing. T-LITEs incorporate a small molecule-controlled switch into a conventional bispecific t-cell engaging antibody which enables precise on/off control over the timing and magnitude of redirected T-cell cytotoxic activity. Soteria was founded in 2018 with technology licensed from UC San Francisco and is based in San Mateo, California.